% | $
Quotes you view appear here for quick access.

Sangamo Biosciences Inc. Message Board

  • gswkool gswkool Mar 8, 2013 4:24 PM Flag

    UPDATE: Wedbush Raises PT to $13 on Sangamo BioSciences on HIV Progress, Time Value

    FYI below....{pls stop talking about AF altogether more posts.., you're psychologically enforcing his need for attention....much like how infant mentalities operate}

    10:50a ET March 7, 2013 (Benzinga) Wedbush maintained Sangamo BioSciences (NASDAQ: SGMO) with an Outperform rating and raised the price target from $10.00 to $13.00.

    Wedbush said, "Sangamo presented immunologic results supporting previous observations about the functionality and durability of SB-728-T modified T-cells at the 20th Conference on Retroviruses and Opportunistic Infections (CROI). … We are reiterating our OUTPERFORM rating and increasing our fair value to $13 from $10 due to HIV progress, error correction, and time value. By focusing on CCR5 heterozygotes, we increased our peak penetration and net peak annual worldwide revenues to Sangamo to about $656 million from about $500 million."

    Sangamo BioSciences closed at $10.26 on Wednesday.

14.91-0.12(-0.80%)Mar 26 4:00 PMEDT